Alphabet, Baidu, Microsoft and Qualcomm all notched up exits as the cloud services provider floated above a range that had already been increased.

Shin Nippon's migraine treatment spinoff, Satsuma Pharmaceuticals, floated above its range to raise $82.5m in an offering that follows $86m of funding.

Osage University Partners has celebrated an exit as migraine treatment developer Satsuma Pharmaceuticals listed on the Nasdaq Global Market following an $82.5m offering.

The SoftBank-backed biological analysis technology provider priced its shares above its range and will likely close the offering at $449m.

The immuno-oncology drug developer, spun out of Johannes Gutenberg University Mainz, has filed for a $100m offering in the US.

Karolinska Institute spinout Aprea Therapeutics has filed to raise approximately $68.3m in an IPO that will see it list on the Nasdaq Global Select Market.

Osage University Partners-backed Satsuma has filed for an $86.3m initial public offering that will fund phase 3 trials of its migraine candidate.

Livongo priced its shares above their range to raise more than $355m, providing exits to Merck GHI, M12, Humana, Zaffre Investments and Echo Health Ventures.

Health Catalyst, which counts several care providers as investors, has raised $182m in its initial public offering, with its share price shooting up more than 50% on the first day of trading.

Phreesia has raised more than $167m in proceeds after pricing shares above its range at $18, providing exits to BlueCross BlueShield, Ascension Health and Echo Health Ventures.